Incidence of Reported Pseudoprogression on <scp> <sup>18</sup> F </scp> ‐ <scp>FDG PET</scp> / <scp>CT</scp> in Metastatic Melanoma Patients Undergoing Immune Checkpoint Inhibitor Immunotherapy
Pseudoprogression on <sup>18</sup>F-FDG PET/CT occurred in approximately 2.5% of metastatic melanoma patients commencing immunotherapy with an average time to subsequent confirmed response of ~6 months. This highlights the importance of not ceasing immunotherapy prematurely based on early <sup>18</sup>F-FDG PET/CT findings.
Authors
- D. Nadebaum
- Martin Cherk (ORCID: https://orcid.org/0000-0003-3961-8679)
- Mark Shackleton (ORCID: https://orcid.org/0000-0002-7673-4655)
- Philip Macilwraith
- Vivek Naranbhai (ORCID: https://orcid.org/0000-0003-4281-8882)
- Andrew Haydon
- Victoria Mar
Institutions
- The Alfred Hospital (AU)
- Monash University (AU)
Publication Details
- Journal
- Journal of Medical Imaging and Radiation Oncology
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1111/1754-9485.70066
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 24.20